Health

Ozempic blindness suits top 200 as Novo Nordisk spends DKK 11 billion on buybacks

Maria David Patten says Ozempic left her permanently blind on a label that never mentioned the risk. Europe ordered semaglutide labels updated in 2025; the FDA has not, and the suits now top 200 while Novo returns cash to shareholders.

Vincent JiangVincent Jiangtwo-minute read
Share
Novo Nordisk chief executive Mike Doustdar in front of a glass facade
1 / 6Slide 1 of 6
Novo Nordisk chief executive Mike Doustdar. The company calls the 200-plus NAION suits without merit.

A label with no mention of blindness

Maria David Patten, a Nevada woman, injected Ozempic0.00% — Ozempic, unchanged today from August 2022 1. In October 2023 her sight failed suddenly 1. Doctors diagnosed non-arteritic anterior ischemic optic neuropathy (NAION), a blockage of blood to the optic nerve, and told her the loss was permanent; it kept worsening 1.

On October 19 she sued Novo Nordisk, the Danish maker of Ozempic, in the Eastern District of Pennsylvania for failure to warn and fraudulent concealment, seeking punitive damages, over a warning label her complaint says still never mentions NAION 1. The case joins the GLP-1 multidistrict litigation before US District Judge Karen Marston, where stomach-paralysis trials are expected to reach juries first 1.

Europe relabeled in 2025; the FDA has not

The complaint says the eye's GLP-1 receptors were documented by 2016, the first optic-ischemic report dates to 2012, a semaglutide-specific case to 2019, and a July 2024 Harvard study found patients on Ozempic or Wegovy seven times more likely to develop NAION than patients on other treatments 1.

Europe's medicines regulator concluded in June 2025 that NAION is a very rare side effect of semaglutide, up to one case in 10,000 and roughly double the risk in type 2 diabetes, and ordered the EU product information updated 2. The FDA does not require NAION on the US label, and its Sentinel review of the signal is still open 3. More than 200 NAION suits now sit in federal court 4.

One cash engine, two claims on it

Novo has fallen more than 60% in two years and trades near 12 times forward earnings against a 19.2 healthcare average, a discount the market explains with Eli Lilly−0.54% — Eli Lilly, down 0.54 percent today and a 2032 patent cliff, not courtrooms 56.

On September 21 it promised five or more new blockbusters by 2030 and DKK 150 billion of pipeline sales by 2035; the stock fell 7.7%, with 2026 guidance for sales and operating profit down 6% to flat 6. Since February it has bought DKK 11.19 billion of its own stock, averaging DKK 277.78 a share, under a DKK 15 billion program 7.

Novo's quarterly sales fell year-on-year in Q2 2026, and operating income followed

  • Sales
  • Operating income
$0B$5B$10B$15BQ4 '23Q2 '24Q4 '24Q2 '25Q4 '25Q2 '26$11.98B$4.13Bfirst year-on-year sales drop inthe series
Data
SalesOperating income
Q3 '23$8.33B$3.82B
Q4 '23$9.76B$3.97B
Q1 '24$9.46B$4.61B
Q2 '24$9.78B$3.73B
Q3 '24$10.52B$4.99B
Q4 '24$11.95B$5.12B
Q1 '25$11.33B$5.63B
Q2 '25$12.08B$5.26B
Q3 '25$11.79B$3.72B
Q4 '25$12.44B$4.99B
Q1 '26$14.85B$9.14B
Q2 '26$11.98B$4.13B
Novo's quarterly sales fell year-on-year in Q2 2026, and operating income followed8

What the defense does not price

Novo calls the US personal-injury suits without merit and cites 58 million patient-years of drug exposure 4; US eye societies say causation is unproven and the risk magnitude low 3. Both can hold and still leave the tail unpriced. The same quarterly cash engine that funds the buyback funds whatever the bellwethers award. The next readings are dated: Marston's trial schedule 1, the FDA's Sentinel conclusion 3, and Novo's own quarterly report before the November 5 to 9 liver congress 9.

The cash engine that funds the buyback also funds whatever the NAION bellwethers award

  • Operating cash flow
  • Free cash flow
-$5B$0B$5B$10BQ4 '23Q2 '24Q4 '24Q2 '25Q4 '25Q2 '26$8.43B
Data
Operating cash flowFree cash flow
Q3 '23$1.9B$2.38B
Q4 '23$5.5B$2.74B
Q1 '24$2.07B$0.85B
Q2 '24$7.26B$5.75B
Q3 '24$6.47B$4.68B
Q4 '24$1.72B-$0.53B
Q1 '25$3.59B$1.64B
Q2 '25$6.57B$4.26B
Q3 '25$7.25B$5.11B
Q4 '25$1.2B-$1.7B
Q1 '26$3.69B$1.96B
Q2 '26$8.43B$6.49B
Quarterly operating and free cash flow, USD billions. Source: Novo Nordisk quarterly figures from its SEC filings, retrieved 31 October 2026.10

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading NVO

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Tempus AI beat Q3, but $80 million of 2027 growth rides on a December 31 Medicare deadline

    Q3 revenue of $411.5 million beat consensus, but the quarterly letter books about $80 million of 2027 growth on a Medicare repricing that only pays if the xT conversion finishes by December 31, while the cheapest product, MRD testing, grows fastest and drags reimbursement down.

    Health

    Eli Lilly puts Foundayo at $149 a month and Zepbound at $299 on Hims & Hers and LifeMD, self-pay

    Two distribution deals in two days put Lilly's Zepbound and Foundayo on Hims & Hers and LifeMD at self-pay prices starting at $149 a month. Lilly keeps the price sheet and the margin; the platforms supply the funnel.

    Health

    Novo Nordisk's 27% profit jump is the adjusted number; the reported number fell 9%

    Novo's beat-and-raise quarter hides a flat underlying US market propped up by a temporary Medicare bridge, and a reported profit that fell 9% while the adjusted line rose 27%. The CFO who called the write-offs one-offs leaves on December 31.

    Health

    Five hospitals say Lilly cut off tens of millions in 340B discounts until they hand over patient data

    Five Massachusetts hospitals say Eli Lilly cut off tens of millions in 340B drug discounts until they surrender patient claims data to a private-equity-owned platform. Lilly calls it fraud policing, and the same gross-to-net machinery under dispute just produced a record $24.4 billion quarter.

    Health

    Retatrutide cut knee pain up to 75.8% in Phase 3, and the fine print matters

    Lilly's first pivotal data for its triple-agonist drug lands at ACR this weekend just as Novo halves Wegovy's list price. The race has split between outcomes and price, and Lilly's headline percentages were never pre-specified.

    Health

    Ambience's KLAS validation put $37,500 a year on each ER doctor; $6.69 billion Abridge sells minutes

    A KLAS validation published November 3 puts about $37,500 of extra annual productivity on each emergency physician at Memorial Hermann, the Houston-based health system, the largest per-provider dollar figure KLAS has validated to date. Abridge, marked at $6.69 billion, has published minutes saved per clinician-day and no validated dollars.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.